What are the potential nail disorders associated with isotretinoin (13-cis-retinoic acid) treatment and how can they be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nail Disorders Associated with Isotretinoin

Isotretinoin causes nail disorders in approximately 34% of patients, with onychoschizia (nail splitting) being the most common manifestation, occurring in over half of affected patients 1.

Common Nail Changes with Isotretinoin

The most frequent nail disorders include:

  • Onychoschizia (nail splitting/fragility) - occurs in 55.9% of patients with nail changes 1
  • Leukonychia (white discoloration) - affects 11.8% of patients with nail changes 1
  • Onychorexis (longitudinal ridging) - seen in 8.8% of cases 1
  • Nail fragility and increased brittleness - commonly reported 2, 3
  • Paronychia (periungual inflammation) - can occur with erythema, edema, and tenderness 4
  • Pyogenic granulomas - rare but notable complication affecting 5.9% of patients with nail changes 1, 4
  • Onycholysis (nail plate separation) - uncommon at 2.9% but well-documented 2, 1
  • Median nail dystrophy - affects 5.9% of patients 1
  • Beau's lines (transverse grooves) - rare at 2.9% 1

Mechanism and Risk Factors

Isotretinoin progressively increases nail growth rate while simultaneously thinning the nail plate over the treatment course 3. The median nail growth rate increases to 3.16 mm/month compared to 2.89 mm/month in untreated patients, while nail thickness decreases significantly 3.

The risk of nail changes correlates with cumulative dose rather than treatment duration 1. This dose-dependent relationship means patients receiving higher total doses face greater risk regardless of how quickly that dose is administered 1.

Management Approach

Prevention Strategies

All patients starting isotretinoin should receive counseling on nail care:

  • Avoid cutting nails too short; trim straight across 5, 6
  • Apply daily emollients to cuticles and periungual tissues 5, 6
  • Avoid nail biting and using nails as tools 5, 6
  • Wear protective gloves during cleaning or water exposure 5, 6
  • Avoid trauma, friction, and excessive pressure to nail units 5, 6

Treatment of Specific Nail Disorders

For nail fragility and onychoschizia:

  • Daily application of topical emollients to nail plate and periungual tissues 5
  • Protective nail lacquers to limit water loss 5
  • These changes are completely reversible after discontinuation 1

For paronychia:

  • Warm antiseptic soaks with dilute vinegar (50:50 dilution) or 2% povidone-iodine twice daily for 10-15 minutes 5, 6
  • Mid to high-potency topical corticosteroid ointment to nail folds twice daily 5, 6
  • If infection suspected (pus present), culture and treat with appropriate antibiotics 5, 6
  • Secondary bacterial or fungal superinfection occurs in up to 25% of paronychia cases 5

For pyogenic granulomas:

  • Topical timolol 0.5% gel twice daily under occlusion for 1 month has shown complete clearance 5
  • Silver nitrate chemical cauterization 5
  • Scoop shave removal with hyfrecation for larger lesions 5, 6
  • Intralesional triamcinolone acetonide for recurrent or severe cases 5, 6

For onycholysis:

  • Daily topical emollients to affected areas 5
  • Avoid further trauma and water exposure 5
  • Monitor for secondary infection requiring antimicrobial therapy 5

Important Clinical Considerations

All isotretinoin-induced nail changes are completely reversible after treatment discontinuation 1. This reassurance is critical for maintaining patient compliance, as nail changes can be distressing and impact quality of life 3, 7.

The nail findings typically appear after several weeks of treatment due to the slow growth rate of the nail plate 5. Fingernails are more commonly affected than toenails 5.

Dose reduction should be considered if nail changes significantly impact quality of life, though complete resolution typically requires treatment cessation 1, 3. The reversible nature of these changes means continuation of therapy is reasonable if the acne severity warrants it and the patient can tolerate the nail symptoms with supportive care 1.

Monitor patients monthly for early signs of nail changes, particularly paronychia and pyogenic granulomas, as early intervention prevents progression to more severe complications 5, 4.

References

Research

Isotretinoin-induced nail fragility and onycholysis.

The Journal of dermatological treatment, 2001

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Ingrown Toenail

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

How to manage median nail dystrophy in a patient taking isotretinoin (13-cis-retinoic acid) for acne treatment?
I'm an adolescent/young adult with acne taking 20mg of isotretinoin (isotretinoin) and developed mild median nail dystrophy, can I reduce the dose to 20mg every other day?
What could be the cause of purple discoloration at the base of the nail beds in a patient, potentially with a history of conditions like diabetes or peripheral artery disease?
What is the significance of bluish discoloration (cyanosis) of the nails on both upper and lower extremities in a patient, potentially indicating poor oxygenation or circulation?
How is Beau's lines condition managed and treated?
How to switch an adult patient with type 2 diabetes from Novo Mix (insulin aspart protamine/insulin aspart) to insulin aspart and insulin glargine as an inpatient?
How do PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitors affect kidney function in patients with pre-existing kidney disease?
What is causing muscle spasms in the neck and leg of a patient after undergoing dialysis?
What are the best treatments for a patient experiencing severe morning back stiffness?
Is there a difference in efficacy between subcutaneous (SC) and intravenous (IV) administration of filgrastim (granulocyte-colony stimulating factor) for hematopoietic stem cell (HSC) mobilization in a patient with relapsed Hodgkin Lymphoma?
How to manage median nail dystrophy in a patient taking isotretinoin (13-cis-retinoic acid) for acne treatment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.